Would induction of dopamine homeostasis via coupling genetic addiction risk score (GARS®) and pro-dopamine regulation benefit benzodiazepine use disorder (BUD)?

بواسطة Blum, K, Gold, M, Modestino, EJ, Baron, D, Boyett, B, Siwicki, D, Lott, L, Podesta, A, Roy, AK, Hauser, M, Downs, BW, Badgaiyan, RD
الحاوية / القاعدة J Syst Integr Neurosci (2018)

Americas’ opioid/psychostimulant epidemic would benefit from general population early identification of genetic addiction risk especially in children of alcoholics (COAs)

بواسطة Blum, K, Baron, D, Hauser, M, Henriksen, S, Thanos, PK, Black, C, Siwicki, D, Modestino, EJ, Downs, BW, Badgaiyan, S, Simpatico, TA, Boyett, B, Badgaiyan, RD
الحاوية / القاعدة J Syst Integr Neurosci (2019)

Molecular neuro-biological and systemic health benefits of achieving dopamine homeostasis in the face of a catastrophic pandemic (COVID- 19): A mechanistic exploration

بواسطة Downs, BW, Blum, K, Bagchi, D, Kushner, S, Bagchi, M, Galvin, JM, Lewis, MCG, Siwicki, D, Brewer, R, Boyett, B, Baron, D, Giordano, J, Badgaiyan, RD
الحاوية / القاعدة J Syst Integr Neurosci (2020)

Biotechnical development of genetic addiction risk score (GARS) and selective evidence for inclusion of polymorphic allelic risk in substance use disorder (SUD)

بواسطة Blum, K, Bowirrat, A, Baron, D, Lott, L, Ponce, JV, Brewer, R, Siwicki, D, Boyett, B, Gondre-Lewis, MC, Smith, DE, Panayotis K, Thanos, Badgaiyan, S, Hauser, M, Fried, L, A., Roy, Downs, BW, Badgaiyan, RD
الحاوية / القاعدة J Syst Integr Neurosci (2019)